<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986855</url>
  </required_header>
  <id_info>
    <org_study_id>8835-001</org_study_id>
    <secondary_id>2013-003587-31</secondary_id>
    <secondary_id>B1521016</secondary_id>
    <nct_id>NCT01986855</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in
      participants with Type 2 diabetes mellitus with Stage 3 Chronic Kidney Disease (CKD) who have
      inadequate glycemic control on background antihyperglycemic therapy. The duration of this
      trial will be up to 67 weeks. This study will consist of a 1-week Screening Period, a 10-week
      wash-off period from metformin, if needed, and a 2-week placebo run-in period, a 52-week
      double-blind treatment period, and a 14-day post-treatment follow-up period. The primary
      objective of this trial is to assess the hemoglobin A1C (A1C)-lowering efficacy of the
      addition of ertugliflozin compared to the addition of placebo with an underlying hypothesis
      that addition of treatment with ertugliflozin provides greater reduction in A1C compared to
      the addition of placebo; the primary objective will be tested for both 5-mg and 15-mg doses
      of ertugliflozin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who meet protocol-defined glycemic rescue criteria will be permitted to have an
      adjustment in the dose(s) of background antihyperglycemic agent (AHA) therapy or addition of
      new AHA therapy as directed by their investigator until the participant no longer meets the
      rescue criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2013</start_date>
  <completion_date type="Actual">September 28, 2016</completion_date>
  <primary_completion_date type="Actual">September 28, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in A1C at Week 26 - Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced an Adverse Event (AE)</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>This change from baseline reflects the Week 26 sitting systolic blood pressure minus the Week 0 sitting systolic blood pressure. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With A1C &lt;7.0% (&lt;53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</measure>
    <time_frame>Week 26</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">468</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin, 5 mg, oral, one 5 mg ertugliflozin tablet and one placebo tablet, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin (15 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin, 15 mg, oral, one 5 mg and one 10 mg tablet, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks</description>
    <arm_group_label>Ertugliflozin (5 mg)</arm_group_label>
    <other_name>MK-8835</other_name>
    <other_name>PF-04971729</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 5 mg</intervention_name>
    <description>Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 10 mg</intervention_name>
    <description>Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks</description>
    <arm_group_label>Ertugliflozin (15 mg)</arm_group_label>
    <other_name>MK-8835</other_name>
    <other_name>PF-04971729</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 10 mg</intervention_name>
    <description>Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks</description>
    <arm_group_label>Ertugliflozin (5 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type 2 diabetes mellitus in accordance with American Diabetes Association
             guidelines

          -  Have Stage 3 chronic kidney disease

          -  On stable diabetes therapy (diet/exercise therapy alone or anti-hyperglycemic agents
             [AHA] monotherapy or combination therapy) for at least 6 weeks prior to study
             participation OR on metformin (with or without diet/exercise therapy or other AHA
             therapy) and is willing to undergo a 10-week metformin wash-off period

          -  Have an estimated glomerular filtration rate (eGFR) of ≥30 to &lt;60 mL/min/1.73m^2

          -  Body Mass Index (BMI) greater than or equal to 18.0 kg/m^2

          -  Male, postmenopausal female or surgically sterile female

          -  If a female of reproductive potential, agrees to remain abstinent or to use (or have
             their partner use) 2 acceptable combinations of birth control while participating in
             the trial and for 14 days after the last use of study drug.

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or a history of ketoacidosis

          -  History of other specific types of diabetes (e.g., genetic syndromes, secondary
             pancreatic diabetes, diabetes due to endocrine disorders, drug - or chemical-induced,
             and post-organ transplant)

          -  History of nephrotic range proteinuria with hypoalbuminemia and edema

          -  History of rapidly progressive glomerulonephritis, lupus nephritis, renal or systemic
             vasculitis, renal artery stenosis with renovascular hypertension, or ischemic
             nephropathy

          -  History of familial renal glucosuria

          -  History of renal dialysis or renal transplant or renal disease requiring treatment
             with any immunosuppressive agent

          -  A known hypersensitivity or intolerance to any (sodium-glucose co-transporter 2) SGLT2
             inhibitor

          -  On a weight-loss program or weight-loss medication or other medication associated with
             weight changes and is not weight stable

          -  Has undergone bariatric surgery within the past 12 months

          -  Has been treated with rosiglitazone or other SGLT2 inhibitors within 12 weeks of study
             participation

          -  Has active, obstructive uropathy or indwelling urinary catheter

          -  History of myocardial infarction, unstable angina, arterial revascularization, stroke,
             transient ischemic attack, or New York Heart Association (NYHA) functional class
             III-IV heart failure within 3 months of study participation

          -  A history of malignancy ≤5 years prior to study participation, except for adequately
             treated basal or squamous cell skin cancer or in situ cervical cancer

          -  Known history of Human Immunodeficiency Virus (HIV)

          -  Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells or
             any other clinically significant hematological disorder (such as aplastic anemia,
             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

          -  A medical history of active liver disease (other than non-alcoholic hepatic
             steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or
             active symptomatic gallbladder disease

          -  Has any clinically significant malabsorption condition

          -  If taking thyroid replacement therapy, has not been on a stable dose for at least 6
             weeks prior to study participation

          -  Has been previously randomized in a study with ertugliflozin

          -  Has participated in other studies involving an investigational drug within 30 days
             prior or during study participation

          -  Has undergone a surgical procedure within 6 weeks prior to or during study
             participation

          -  Has a positive urine pregnancy test

          -  Is pregnant or breast-feeding, or is planning to conceive during the trial, including
             14 days following the last dose of study medication

          -  Planning to undergo hormonal therapy in preparation to donate eggs during the trial,
             including 14 days following the last dose of study medication

          -  Excessive consumption of alcoholic beverages or binge drinking

          -  Has donated blood or blood products within 6 weeks of study participation or plans to
             donate blood or blood products at any time during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, Jiang ZW, Golm G, Engel SS, Lauring B. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Ther. 2018 Feb;9(1):49-66. doi: 10.1007/s13300-017-0337-5. Epub 2017 Nov 20.</citation>
    <PMID>29159457</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <results_first_submitted>September 5, 2017</results_first_submitted>
  <results_first_submitted_qc>October 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2017</results_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted in 13 countries, including 171 trial centers; 1709 participants were screened and 468 were randomized.</recruitment_details>
      <pre_assignment_details>Eligible participants began a ≥10-week metformin wash-off during which participant’s antihyperglycemic agents (AHAs) could be adjusted.
All participants entered a 2-week placebo run-in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Ertugliflozin 15 mg</title>
          <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Overall Number of Baseline Participants was the All-Participants-As-Treated population.</population>
      <group_list>
        <group group_id="B1">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Ertugliflozin 15 mg</title>
          <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="158"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="154"/>
            <count group_id="B4" value="467"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="158"/>
                    <count group_id="B2" value="155"/>
                    <count group_id="B3" value="154"/>
                    <count group_id="B4" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="8.3"/>
                    <measurement group_id="B2" value="67.5" spread="8.5"/>
                    <measurement group_id="B3" value="67.5" spread="8.9"/>
                    <measurement group_id="B4" value="67.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="158"/>
                    <count group_id="B2" value="155"/>
                    <count group_id="B3" value="154"/>
                    <count group_id="B4" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="236"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Hemoglobin A1C (A1C)</title>
          <population>Participants with baseline data for A1C.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="154"/>
                    <count group_id="B2" value="151"/>
                    <count group_id="B3" value="152"/>
                    <count group_id="B4" value="457"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.20" spread="1.02"/>
                    <measurement group_id="B2" value="8.17" spread="0.87"/>
                    <measurement group_id="B3" value="8.08" spread="0.89"/>
                    <measurement group_id="B4" value="8.15" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="158"/>
                    <count group_id="B2" value="155"/>
                    <count group_id="B3" value="154"/>
                    <count group_id="B4" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.4" spread="22.5"/>
                    <measurement group_id="B2" value="85.8" spread="17.4"/>
                    <measurement group_id="B3" value="90.4" spread="18.9"/>
                    <measurement group_id="B4" value="88.5" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Fasting Plasma Glucose (FPG)</title>
          <population>Participants with baseline data for FPG.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="157"/>
                    <count group_id="B2" value="155"/>
                    <count group_id="B3" value="154"/>
                    <count group_id="B4" value="466"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160.9" spread="56.4"/>
                    <measurement group_id="B2" value="157.5" spread="47.8"/>
                    <measurement group_id="B3" value="156.9" spread="56.4"/>
                    <measurement group_id="B4" value="158.5" spread="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Estimated glomerular filtration rate (eGFR)</title>
          <description>Stratification Factor: eGFR (mL/min/1.73m^2)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≥30 to &lt;45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="158"/>
                    <count group_id="B2" value="155"/>
                    <count group_id="B3" value="154"/>
                    <count group_id="B4" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥45 to &lt;60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="158"/>
                    <count group_id="B2" value="155"/>
                    <count group_id="B3" value="154"/>
                    <count group_id="B4" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Insulin at randomization</title>
          <description>Insulin at randomization? (Yes/No)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="158"/>
                    <count group_id="B2" value="155"/>
                    <count group_id="B3" value="154"/>
                    <count group_id="B4" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="158"/>
                    <count group_id="B2" value="155"/>
                    <count group_id="B3" value="154"/>
                    <count group_id="B4" value="467"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in A1C at Week 26 - Excluding Rescue Approach</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The analysis population included all randomized participants who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 A1C endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 26 - Excluding Rescue Approach</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all randomized participants who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 A1C endpoint.</population>
          <units>Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" lower_limit="-0.44" upper_limit="-0.14"/>
                    <measurement group_id="O2" value="-0.41" lower_limit="-0.56" upper_limit="-0.27"/>
                    <measurement group_id="O3" value="-0.26" lower_limit="-0.41" upper_limit="-0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.807</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, eGFR stratum (&lt;45 or ≥45 mL/min/1.73m^2), baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.155</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, eGFR stratum (&lt;45 or ≥45 mL/min/1.73m^2), baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced an Adverse Event (AE)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 54 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced an Adverse Event (AE)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8"/>
                    <measurement group_id="O2" value="74.2"/>
                    <measurement group_id="O3" value="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentages vs. Placebo</param_type>
            <param_value>3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>12.1</ci_upper_limit>
            <estimate_desc>Miettinen &amp; Nurminen Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentages vs. Placebo</param_type>
            <param_value>-7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.3</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>Miettinen &amp; Nurminen Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Treatment Due to an AE</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Treatment Due to an AE</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all randomized participants who received at least 1 dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentages vs. Placebo</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
            <estimate_desc>Miettinen &amp; Nurminen Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentages vs. Placebo</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
            <estimate_desc>Miettinen &amp; Nurminen Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The analysis population included all randomized participants with a Baseline eGFR of ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 A1C endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all randomized participants with a Baseline eGFR of ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 A1C endpoint.</population>
          <units>Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" lower_limit="-0.49" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.37" lower_limit="-0.56" upper_limit="-0.18"/>
                    <measurement group_id="O3" value="-0.28" lower_limit="-0.47" upper_limit="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.828</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.496</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
        <description>This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The analysis population included all randomized participants with a Baseline eGFR of ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 body weight endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
          <description>This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all randomized participants with a Baseline eGFR of ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 body weight endpoint.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" lower_limit="-1.86" upper_limit="-0.76"/>
                    <measurement group_id="O2" value="-1.39" lower_limit="-1.97" upper_limit="-0.81"/>
                    <measurement group_id="O3" value="0.46" lower_limit="-0.13" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable. P-value is nominal.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.57</ci_lower_limit>
            <ci_upper_limit>-0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable. P-value is nominal.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.66</ci_lower_limit>
            <ci_upper_limit>-1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
        <description>This change from baseline reflects the Week 26 sitting systolic blood pressure minus the Week 0 sitting systolic blood pressure. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The analysis population included all randomized participants with a Baseline eGFR of ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 sitting systolic blood pressure endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
          <description>This change from baseline reflects the Week 26 sitting systolic blood pressure minus the Week 0 sitting systolic blood pressure. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all randomized participants with a Baseline eGFR of ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 sitting systolic blood pressure endpoint.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" lower_limit="-4.98" upper_limit="0.33"/>
                    <measurement group_id="O2" value="-4.36" lower_limit="-7.11" upper_limit="-1.62"/>
                    <measurement group_id="O3" value="-0.90" lower_limit="-3.73" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.451</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-3.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.24</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
        <description>This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The analysis population included all randomized participants with a Baseline eGFR ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 FPG endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
          <description>This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all randomized participants with a Baseline eGFR ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at or after baseline for the change from baseline at Week 26 FPG endpoint.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.76" lower_limit="-21.07" upper_limit="-2.45"/>
                    <measurement group_id="O2" value="-20.47" lower_limit="-30.20" upper_limit="-10.73"/>
                    <measurement group_id="O3" value="-4.95" lower_limit="-15.03" upper_limit="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.291</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-6.81</param_value>
            <ci_percent>96</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.47</ci_lower_limit>
            <ci_upper_limit>5.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>The cLDA model included fixed effects for treatment, time, baseline treatment with insulin stratum (yes/no), and the interaction of time by treatment. Time was treated as a categorical variable. P-value is nominal.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-15.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.50</ci_lower_limit>
            <ci_upper_limit>-2.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With A1C &lt;7.0% (&lt;53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Week 26</time_frame>
        <population>The analysis population included all randomized participants with a Baseline eGFR ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at Week 26 for the percentage of participants with an A1C &lt;7% at Week 26 endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With A1C &lt;7.0% (&lt;53 mmol/Mol) at Week 26 - Baseline eGFR ≥45 to &lt;60 mL/Min/1.73m^2 Stratum - Excluding Rescue Approach</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all randomized participants with a Baseline eGFR ≥45 to &lt;60 mL/min/1.73m^2 and who took at least 1 dose of study treatment and had at least 1 assessment at Week 26 for the percentage of participants with an A1C &lt;7% at Week 26 endpoint.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="11.3"/>
                    <measurement group_id="O3" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.713</p_value>
            <p_value_desc>Adjusted Odds Ratio based on a logistic regression model fitted with fixed effects for treatment, baseline treatment with insulin stratum (yes/no), and a covariate for baseline A1C.</p_value_desc>
            <method>Logistic regression model</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.890</p_value>
            <p_value_desc>Adjusted Odds Ratio based on a logistic regression model fitted with fixed effects for treatment, baseline treatment with insulin stratum (yes/no), and a covariate for baseline A1C.</p_value_desc>
            <method>Logistic regression model</method>
            <param_type>Adjusted Odds Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 54 weeks</time_frame>
      <desc>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo, oral, tablet, 5-mg or 5-mg and 10-mg tablet once daily for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin, oral, 5-mg tablet once daily for 52 weeks. Participants also received a 10-mg matching placebo tablet once daily for 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Ertugliflozin 15 mg</title>
          <description>Ertugliflozin, oral, 5-mg and 10-mg tablet once daily for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="158"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph node haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cyclic vomiting syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoma in situ of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sciatic nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="158"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="158"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="158"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="216" subjects_affected="45" subjects_at_risk="154"/>
                <counts group_id="E2" events="423" subjects_affected="49" subjects_at_risk="158"/>
                <counts group_id="E3" events="281" subjects_affected="32" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>After unblinding, analysis of retained plasma samples revealed unreported metformin use by ~17% of participants. Neither dose nor frequency of the protocol-prohibited metformin use is known. This potentially confounds glycemic analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

